PepLib Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

PepLib Biotech is a China-based, privately held biotech focused on next-generation peptide drug discovery. The company has built a suite of proprietary technology platforms, including peptide library generation and screening technologies, to accelerate the identification of novel therapeutic candidates. It has secured high-profile partnerships with Novartis, Eli Lilly, and AstraZeneca, indicating validation of its platform, and has progressed to a Series B financing round to advance its pipeline. The company's strategy combines internal pipeline development with strategic out-licensing and collaboration deals.

Drug DeliverySmall Molecules

Technology Platform

Suite of proprietary peptide discovery platforms including PICT, DRP-PD, Nano-Cyclic Peptide Library, Animal Toxin Peptide Library, Virtual Peptide Library, and mRNA Display Library for generating and screening diverse peptide candidates.

Opportunities

The growing peptide therapeutics market, driven by advances in delivery and design, offers a multi-billion dollar opportunity.

PepLib's validated platform positions it to secure more high-value pharma partnerships and advance internal assets into clinical development, particularly in high-interest areas like radioligand therapy and cyclic peptides for intracellular targets.

Risk Factors

Key risks include technological hurdles in translating peptide hits into viable drugs, pipeline concentration in a few partnered programs, intense competition in the peptide space, and potential geopolitical complexities arising from its China-based headquarters with U.S.

operations.

Competitive Landscape

PepLib competes in a crowded peptide discovery landscape against other platform companies (e.g., Bicycle Therapeutics, PeptiDream) and large pharma internal efforts. Its differentiation lies in its integrated suite of platforms, including a focus on animal toxins and mRNA display, and its early success in securing top-tier pharma partnerships validates its competitive approach.

More companies in Small Molecule Drugs →More companies in United States →